Filing Flows › Camp4 Therapeutics (CAMP) › Q1 2026
Camp4 Therapeutics (CAMP) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Camp4 Therapeutics (CAMP) reported revenue of $1.3M for the first quarter 2026 (Q1 2026), +51% from a year earlier and +272% from the quarter before.
Camp4 Therapeutics, Q1 2026: revenue $1.3M (+51% year over year), net loss $18.3M, operating cash flow −$11.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | +272% | +51% |
| Operating profit | −$13.1M | — | — |
| Net earnings | −$18.3M | — | — |
| Operating cash flow | −$11.0M | — | — |
What changed
Revenue was $1.3M in Q1 2026, up 51% year over year and up 272% from the previous quarter.
Operating costs exceeded revenue by $13.1M, an operating margin of -1010.1%. Total costs grew 3% against revenue growth of 51%. The fastest-growing cost line was General & admin (+10%). The quarter ended with a net loss of $18.3M, narrower than the previous quarter's $40.3M loss.
Operating cash flow was −$11.0M. Non-cash charges added back $520K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items added $5.4M.
Questions
What was Camp4 Therapeutics' revenue in the first quarter 2026?
Camp4 Therapeutics (CAMP) reported revenue of $1.3M for the first quarter 2026 (Q1 2026), +51% from a year earlier and +272% from the quarter before.
Source: Camp4 Therapeutics 10-Q on SEC EDGAR.